BRUKER CORP(BRKR)— Stock Profile, AI Score & Financials
Technology · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
BRUKER CORP (BRKR) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores BRKR at 50.8/100 on a 32-signal composite quality model, placing it at rank #1,569 of 2,962 stocks — the bottom half of the AI-ranked universe. BRKR scores in the top quartile across earnings quality (78.1). Areas of concern include profitability (25.1) and balance sheet strength (30.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), BRUKER CORP reports quarterly revenue of $838.5M, net income of $-52.0M, free cash flow of $-106.2M. Top institutional holders of BRKR by reported 13-F value include FMR, Orbis Allan Gray Ltd, BlackRock, based on the most recent SEC filings. BRKR trades on the Nasdaq exchange and files with the SEC under CIK 1109354. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BRKR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BRUKER CORP directly from SEC EDGAR.
AI Quality Score
50.8/100
AI Rank
#1,569
Revenue
$838.5M
Net Income
$-52.0M
Free Cash Flow
$-106.2M
BRKR key financials by period
BRUKER CORP reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$3.4B
$-8.6M
2.0%
FY 2024
10-K
$3.4B
$113.1M
7.5%
FY 2023
10-K
$3.0B
$427.2M
14.7%
FY 2022
10-K
$2.5B
$296.6M
17.1%
FY 2021
10-K
$2.4B
$277.1M
17.1%
FY 2020
10-K
$2.0B
$157.8M
12.5%
Institutions holding BRKR
Institutional investors reporting a position in BRUKER CORP on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-05 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Bruker reported Q2 revenue of $838.5M (+5.2% YoY) but swung to a $65.3M operating loss due to $134.9M goodwill impairment charges in BioSpin and NANO segments.
Biggest Revenue Drivers
BSI CALID$310.3M+8.6% YoY
Driven by impact of recent acquisitions and increased revenue from academic/government research and biotech/pharma markets.
BSI NANO$261.3M+3.6% YoY
Remained consistent with prior year period.
Biggest Revenue Drivers
Total revenue: $838.5M+5.2% YoY
BSI CALID$310.3M+8.6% YoY
Driven by impact of recent acquisitions and increased revenue from academic/government research and biotech/pharma markets.
BSI NANO$261.3M+3.6% YoY
Remained consistent with prior year period.
BSI BioSpin$195.7M+0.2% YoY
Revenue remained consistent during the quarter.
BEST$74.2M+11.9% YoY
Growth driven by superconductor business and fusion energy/high-energy physics technologies.
Largest Expense Items
Goodwill impairment charge$134.9MN/A
Impairment of BSI BioSpin Chemspeed Technologies ($98.4M) and BSI NANO Bruker Spatial Biology ($36.5M) reporting units due to reduced revenue and cash flow forecasts.
Cost of revenue$422.5M-3.9% YoY
Decrease driven by cost savings initiatives, positive net U.S. tariffs impact, and higher revenue volume.
Selling, general and administrative$238.9M+3.2% YoY
Impact of cost savings initiatives offset by acquisitions, foreign exchange headwinds, and cost inflation.
Research and development$94.3M-5.9% YoY
Decrease driven by cost saving initiatives.
Margins: Gross margin expanded to 49.6% from 44.9% YoY due to cost savings, tariff refunds, and revenue volume, but operating margin deteriorated sharply to -7.8% from +1.5% due to the $134.9M goodwill impairment charges and foreign exchange headwinds.
Watch Items from the Filing
$134.9M goodwill impairment charges recorded in Q2 2026 across two reporting units (BSI BioSpin Chemspeed $98.4M, BSI NANO Bruker Spatial Biology $36.5M) due to reduced revenue/cash flow forecasts.
Post-June 30 segment reorganization triggered interim goodwill impairment analysis on several reporting units; additional impairment charges expected in Q3 2026.
BSI BioSpin segment operating loss of $64.6M in Q2 2026 versus $18.1M operating income in Q2 2025, driven primarily by goodwill impairment of CST reporting unit.
Asia Pacific revenue declined 10.2% YoY in Q2 2026 and 10.3% YoY for six months ended June 30, 2026, reflecting weakness in key geographic markets.
Company completed settlement of patent litigation with 10x Genomics and AbCellera in first half of 2026; all settlement payments made and no remaining liabilities outstanding.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
